Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

FK 633

Known as: FK-633, FK633 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Recently, by employing intra-vital confocal microscopy, we demonstrated that platelets expose phosphatidylserine (PS) and fibrin… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2008
2008
INTRODUCTION Blood contact with artificial surfaces of extracorporeal circulation (ECC) and hypothermia as applied in cardiac… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • table 1
2004
2004
OBJECTIVE Temporary pharmacologic inhibition of platelet function during and after cardiopulmonary bypass (CPB) (platelet… Expand
2003
2003
OBJECTIVE Contact between blood and the synthetic surfaces of a cardiopulmonary bypass circuit leads to platelet activation, and… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
1998
1998
Antiplatelet and antithrombotic effects of FK633 (a GPIIb/IIIa antagonist) and aspirin were compared. FK633 at 0.32 mg/kg i.v. or… Expand
1998
1998
125I-fibrinogen bound to ADP-activated fixed platelets in a saturable manner. The Scatchard plot was curvilinear but nonlinear… Expand
Highly Cited
1997
Highly Cited
1997
Previous work has shown that the type strain of Streptococcus sanguis, NCTC 7863, induces aggregation of normal platelets by a… Expand
1997
1997
The antithrombotic and restenosis-preventing effects of FK633, an inhibitor of platelet aggregation via binding to the… Expand
1996
1996
The anti-platelet and anti-thrombotic properties of FK633, a peptide mimetic GPIIb/IIIa antagonist were studied. In human… Expand
1996
1996
We recently reported a novel hydrophobic descriptor for quantitative structure-activity relationship (QSAR) studies, the… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 4